SingleImmune & Gut

Teduglutide 5mg

Teduglutide is a degradation-resistant GLP-2 analog studied for mucosal growth and intestinal adaptation in short bowel syndrome models.

Mechanism

Binds to GLP-2 receptors on subepithelial myofibroblasts and enteric neurons to trigger the paracrine release of growth mediators like IGF-1, stimulating crypt cell proliferation and mucosal expansion.

Dosing

The documented baseline protocol is 0.05 mg/kg body weight administered once daily via subcutaneous injection without titration.

Reconstitution

Reconstitute the 5 mg lyophilized vial with 0.5 mL of sterile diluent to establish a working concentration of 10 mg/mL.

Storage

Store unopened lyophilized vials at 20°C to 25°C away from direct light, and use reconstituted solutions within 3 hours without freezing.

Mix & measure Teduglutide 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Teduglutide 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration10.0mg/mL

Draw volume0.005mL

On the syringe0.500units

Total doses in vial: 100.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Baseline (40 kg)	2.0 mg once daily (0.05 mg/kg)	20 units (0.20 mL)
Baseline (60 kg)	3.0 mg once daily (0.05 mg/kg)	30 units (0.30 mL)
Baseline (~76 kg ceiling)	3.8 mg once daily (0.05 mg/kg)	38 units (0.38 mL)
Renal Adjustment (eGFR <60)	0.025 mg/kg once daily	Half standard volume

Reconstitution Steps

1
Cleanse the rubber stoppers of both the lyophilized teduglutide vial and the diluent vial with fresh alcohol swabs, permitting them to air-dry completely.
2
Draw precisely 0.5 mL of sterile diluent using an appropriate research syringe.
3
Insert the needle at a slight angle and direct the stream gently down the interior glass wall to prevent shearing the peptide.
4
Allow the vial to rest undisturbed for approximately 30 seconds, then roll smoothly between the hands until the cake is fully dissolved.
5
Inspect the finished 10 mg/mL solution to ensure it is entirely clear and free of particulates before administration within the 3-hour stability window.

Supplies Needed

Peptide Vial

5 mg lyophilized teduglutide cake

Insulin Syringes (U-100)

Subcutaneous measurement and administration calibrated to 100 units per mL

Bacteriostatic Water

Sterile diluent used to reconstitute the lyophilized powder (0.5 mL required)

Alcohol Swabs

Antiseptic preparation of vial tops and injection research surfaces

Why researchers study it

Investigation of GLP-2 receptor-driven mucosal hypertrophy

Parenteral nutrition weaning models in intestinal resection

Analysis of paracrine growth factor cascades (IGF-1, KGF) in gut repair

Assessment of non-genotoxic trophic acceleration risks

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Teduglutide is a synthetic 33-amino-acid peptide engineered as an analog of glucagon-like peptide-2 (GLP-2), a primary physiological regulator of intestinal epithelial growth and mucosal integrity. By substituting alanine with glycine at position 2, the peptide resists enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), dramatically extending its biological half-life compared to endogenous GLP-2. In clinical medicine, this molecule represents the standard of care for adult and pediatric short bowel syndrome dependent on parenteral nutrition, where it functions to expand intestinal absorptive surface area. In investigative laboratories, teduglutide serves as a targeted tool for examining enterocyte proliferation, mucosal architecture preservation, and gut barrier kinetics under severe structural deficits. Because its biological impact is potently trophic, experimental exploration requires rigorous oversight to balance mucosal hypertrophy with cellular surveillance models. It remains exclusively documented within structured intestinal failure investigations, with no empirical basis supporting off-target systemic or mild gastrointestinal applications.

References

1.DailyMed / FDA, Prescribing Information, 2025 — GATTEX (teduglutide) label specifications and safety protocols
2.Jeppesen et al., Gastroenterology, 2012 — Pivotal STEPS trial demonstrating reduced parenteral support requirements in short bowel syndrome
3.Jeppesen et al., Gut, 2011 — Phase 3 dose-ranging investigation of teduglutide efficacy and villus adaptation
4.Schwartz et al., Clinical and Translational Gastroenterology, 2016 — STEPS-2 long-term safety and enteral autonomy extension study
5.Rowland & Brubaker, American Journal of Physiology: Gastrointestinal and Liver Physiology, 2011 — Paracrine mechanisms and non-crypt localization of GLP-2 receptors
6.Buchman et al., Inflammatory Bowel Disease, 2010 — Evaluation of teduglutide in moderate to severe Crohn's disease
7.Marier et al., Expert Opinion on Investigational Drugs, 2008 — Molecular modifications and DPP-4 degradation resistance of ALX-0600
8.Wong et al., BMC Gastroenterology, 2014 — Assessment of teduglutide on gastric emptying rates in healthy volunteers